At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
plerixafor +1 moredrug
Likely dose
plerixafor 160mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
In Brief
A Phase 2 clinical trial evaluating plerixafor and filgrastim for Multiple Myeloma and 4 related conditions. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
Rationale: Giving colony-stimulating factors, such as G-CSF and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Purpose: This phase II trial is studying how well plerixafor works in patients with multiple myeloma previously treated with lenalidomide and planning to undergo autologous stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartDec 2009
Primary CompletionNov 2011
Study CompletionApr 2015
TodayJul 2026
First PostedOct 20, 2009
Enrollment StartDec 1, 2009
Primary CompletionNov 1, 2011
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.7 years ago
Interventions
plerixafordrug
Plerixafor 160mg/kg/dose by IV on days 5-8
filgrastimdrug
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.